ALLMedicine™ Myoclonic Epilepsy Center
Research & Reviews 605 results
Brain & Development; Pietrafusa N, La Neve A et. al.
Mar 30th, 2021 - Our goal was to investigate the long-term clinical course of juvenile myoclonic epilepsy (JME) in a cohort of patients and to identify prognostic factors for refractoriness and seizure relapse after anti-seizure medications (ASMs) withdrawal. A li...
Epilepsia Gesche J, Antonson S et. al.
Mar 18th, 2021 - To investigate social outcome and psychiatric comorbidity of patients with idiopathic/genetic generalized epilepsies (IGEs) and its subtypes (epilepsy with generalized tonic-clonic seizures alone [EGTCS], juvenile absence epilepsy [JAE], and juven...
Epilepsia Turco F, Bonanni E et. al.
Mar 18th, 2021 - Markers of seizure recurrence are needed to personalize antiseizure medication (ASM) therapy. In the clinical practice, EEG features are considered to be related to the risk of seizure recurrence for genetic generalized epilepsies (GGE). However, ...
European Journal of Medical Genetics; Henige H, Kaur S et. al.
Feb 27th, 2021 - The homozygous missense variant in the GOSR2 gene (c.430G > T) is known to be associated with progressive myoclonic epilepsy (PME). The clinical presentation of GOSR2-related PME involves the development of ataxia, seizures, scoliosis, areflexia, ...
Clinical Neurophysiology : Official Journal of the Intern... Lopes MA, Krzemiński D et. al.
Feb 26th, 2021 - For people with idiopathic generalized epilepsy, functional networks derived from their resting-state scalp electrophysiological recordings have shown an inherent higher propensity to generate seizures than those from healthy controls when assesse...
Drugs 287 results see all →
Clinicaltrials.gov 897 results
Apr 25th, 2021 - Levetiracetam tablet is indicated for adjunctive therapy in the treatment of: • Partial onset seizures in patients one month of age and older with epilepsy (1.1) • Myoclonic seizures in patients 12 years of age and older with juvenile myoclonic ep...
Apr 16th, 2021 - Levetiracetam is indicated for the treatment of partial-onset seizures in patients 1 month of age and older (1.1) Levetiracetam is indicated for adjunctive therapy in the treatment of: •Myoclonic seizures in patients 12 years of age and older with...
Apr 16th, 2021 - Levetiracetam Oral Solution USP is indicated for the treatment of partial-onset seizures in patients 1 month of age and older ( 1.1) Levetiracetam Oral Solution USP is indicated for adjunctive therapy for the treatment of: •Myoclonic seizures in p...
Apr 15th, 2021 - Levetiracetam is indicated for the treatment of partial-onset seizures in patients 1 month of age and older (1.1) Levetiracetam is indicated for adjunctive therapy for the treatment of: •Myoclonic seizures in patients 12 years of age and older wit...
Apr 15th, 2021 - Recent Major Changes Section Indications and Usage (1.1) 10/2019 Dosage and Administration (2.2, 2.6) 10/2019 Indications & Usage Section Levetiracetam is indicated for the treatment of partial-o...
News 5 results
Michele G. Sullivan
Dec 20th, 2018 - NEW ORLEANS – Abnormalities of hippocampal volume and morphology in children with temporal lobe or juvenile myoclonic epilepsy (JME) are also present in the brains of their unaffected siblings, although to a lesser extent, based on findings from t.
Oct 24th, 2018 - The cortical regions of the brains of patients with juvenile myoclonic epilepsy (JME) are more likely to be disassociated from subcortical structures, according to a recent study that compared the MRI readings of JME patients to those of normal ch.
Mar 1st, 2014 - Complex Febrile Seizures. Firm recommendations regarding the management of complex febrile seizures are currently lacking.
Jan 23rd, 2014 - In a retrospective cohort study analyzing seizure outcome in 66 patients with juvenile myoclonic epilepsy (JME) followed for a mean of nearly 45 years, investigators in Berlin, Germany, found that seizure remission occurred in 59. 1% of patients, w.
Jul 1st, 2012 - Of 31 patients with juvenile myoclonic epilepsy (JME), 21 (67. 7%) became seizure-free after a follow-up of at least 25 years, according to a study published in the June 12 online Epilepsia.